Advertisement

Stellenwert medikamentöser Therapiemaßnahmen bei Uterus myomatosus

  • T. Kühn

Zusammenfassung

Bei 25 % aller Frauen im reproduktionsfähigen Alter werden Myome des Uterus diagnostiziert. 20–50% aller Myomträgerinnen zeigen Symptome durch Verdrängungserscheinungen oder atypische Blutungen und bedürfen somit einer Therapie (Buttram u. Reiter 1981; Vollenhoven et al. 1990). Myome und ihre Folgesymptome stellen die häufigste Indikation für eine Gebärmutterentfernung dar. 30% aller Hyster-ektomien werden wegen eines myomatös veränderten Uterus durchgeführt (Wilcox 1994).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Acien P, Quereda F (1996) Abdominal myomectomy: results of a simple operative technique. Fertil Steril 65: 41–51PubMedGoogle Scholar
  2. Aleem FA, Predanik M (1995) The hemodynamic effect of GnRH agonist therapy on uterine leiomyoma vascularity: a prospective study using transvaginal color Doppier sonography. Gynecol Endocrinol 9: 253–258PubMedCrossRefGoogle Scholar
  3. Beyth Y (1990) Gonadotropin-releasing hormone analog treatment should not procede conservative myomectomy. Fertil Steril 1: 187–188Google Scholar
  4. Buttram VC, Reiter RC (1981) Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 36: 433–445PubMedGoogle Scholar
  5. Campo S, Garcea N (1999) Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotropin-releasing hormones analogues. Human Reproduction 14: 44–48PubMedCrossRefGoogle Scholar
  6. Candiani GB, Vercellini P, Fedele L, Arcaini L, Bianchi ST, Candiani M (1990) Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri. Acta Obstet Gynecol Scand 69: 413–415PubMedCrossRefGoogle Scholar
  7. Christiansen C, Christensen MS, Transbol I (1981) Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1: 459–461PubMedCrossRefGoogle Scholar
  8. Cirkel U, Ochs H, Roehl A, Schneider HPG (1992) Experience with leuprorelin acetate depot in the treatment of fibroids: A German multicenter study. Clin Ther 14 (Suppl A): 37–50PubMedGoogle Scholar
  9. Cohen D, Mazur MT, Jozefczyk MA et al. (1994) Hyalinization and cellular changes in uterine leiomyomata after gonadotropin-releasing hormone agonist therapy. J Reprod Med 39: 377–380PubMedGoogle Scholar
  10. Deligdisch L, Hirschmann S, Altchek A (1997) Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata. Fertil Steril 67: 837–841PubMedCrossRefGoogle Scholar
  11. Devogelaer JP, Nagant de Deuxchaisnes C, Donnez J, Thomas K (1987) LHRH analogues and bone loss. Lancet 1: 1498PubMedCrossRefGoogle Scholar
  12. Filicori M, Hall DA, Loughlin JS, Rivier J, Vale W, Crowley WF (1983) A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue. Am J Obstet Gynecol 147: 726–727PubMedGoogle Scholar
  13. Friedman AJ, Barbieri RL, Benacerraf B, Schiff I (1987) Treatment of leiomyomata with intranasal or subeutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil Steril 48: 560–564PubMedGoogle Scholar
  14. Friedman AJ, Barbieri RL, Doubilet PM, Fine C, Schiff I (1988) A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprgesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 49: 404–409PubMedGoogle Scholar
  15. Friedman A, Rein M, Harrison-Atlas D, Garfìeld J, Doubilet P (1989) A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil Steril 52: 728–733PubMedGoogle Scholar
  16. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD (1991) Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. Obstet Gynecol 77: 720–725PubMedGoogle Scholar
  17. Friedman A, Daly M, Juneau-Norcross M, Rein MS (1992) Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo. Fertil Steril 58: 205–208PubMedGoogle Scholar
  18. Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, Leboff M (1994) Long-term medical therapy for leiomyomata uteri: A prospective, randomized study of leuprorelide acetate depot plus either oestrogen-progestin or progestin »add-back « for 2 years. Hum Reprod 9: 1618–1625PubMedGoogle Scholar
  19. Gerris J, Degueldre M, Peters A, Romao F, Stjernquist M (1996) The place of Zoladex in deferred surgery for uterine fìbroids. Hormone Res 45(6): 279–284PubMedCrossRefGoogle Scholar
  20. Golan A, Bukovsky I, Pansky M, Schneider D, Weinraub Z, Caspi E (1993) Pre-operative gonadotropin-releasing hormone agonist treatment in surgery for uterine leiomyomata. Hum Reprod 8: 450–452PubMedGoogle Scholar
  21. Gudmundsson JA, Ljunghall S, Bergquist C, Wide L, Nillius SJ (1987) Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition. J Clin Endocrinol Metab 65: 159–163PubMedCrossRefGoogle Scholar
  22. Healy D, Lawson S, Abbott M, Baird DT, Fraser HM (1986) Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone releasing hormone agonist commencing in the luteal phase. J Clin Endocrinol Metab 63: 619–625PubMedCrossRefGoogle Scholar
  23. Lumsden MA, West CP, Baird DT (1987) Goserelin therapy before surgery for uterine fibroids. Lancet 1: 36–37PubMedCrossRefGoogle Scholar
  24. Lumsden MA, West CP, Thomas E, Coutts J, Hillier H, Thomas N, Baird DT (1994) Treatment with the gonadotrohin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids. Br J Obstet Gynecol 101: 438–442CrossRefGoogle Scholar
  25. Maheux R, Grilloteau C, Bastide A, Fazekas ATA (1985) Luteinizing hormone-releasing hormone agonist and uterine leiomyoma : a pilot study. Am J Obstet Gynecol 152: 1034–1038PubMedGoogle Scholar
  26. Maheux R, Lemay A (1992) Treatment of peri-menopausal women: potential long-term therapy with a depot GnRH agonist combined with hormone replacement therapy. Br J Obstet Gynecol 99 Suppl 7: 13–17CrossRefGoogle Scholar
  27. Matta WH, Stabile I, Shaw RW, Campbell S (1988) Doppier assessment of uterine blood flow changes in patients with fibroid receiving the gonadotropin-releasing hormone agonist buserelin. Fertil Steril 49(6): 1083–1085PubMedGoogle Scholar
  28. McLachlan RI, Healy DL, Burger HG (1986) Clinical aspects of LHRH agonist buserelin. Br J Obstet Gynecol 96: 200–206Google Scholar
  29. Nilas L, Christiansen C (1987) Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab 65: 697–702PubMedCrossRefGoogle Scholar
  30. Perrot-Applanat M, Groyer-Picard MT, Garcia E, Lorenzo F, Milogrom E (1988) Immunocytochemical demonstration of estrogen and progesteron receptors in muscle cells of uterine arteries in rabbits and humans. Endocrinology 123: 1511PubMedCrossRefGoogle Scholar
  31. Pickersgill A (1998) GnRH agonists and add-back therapy: is there a perfect combination? Br J Obstet Gynecol 105(5): 475–485CrossRefGoogle Scholar
  32. Reinsch RC, Murphy AA, Morales AJ, Yen SS (1994) The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomised study. Am J Obstet Gynecol 170: 1623–1627PubMedGoogle Scholar
  33. Römer T (1996) Zum Wert der Vorbehandlung mit Gonadotropin-Releasing-Hormon-Agonisten vor der transzervikalen Resektion solitärer submuköser Myome. Gynaekol Geburtshilfliche Rundsch 36: 194 - 196CrossRefGoogle Scholar
  34. Schweppe KW (1992) Vergleichende Untersuchung zur medikamentösen Behandlung von Uterusmyomen mit GnRH-Agonisten - Buserelin intranasal versus Goserelin Depot parenteral. Fertilität 8: 183 - 187Google Scholar
  35. Simberg N, Tiitinen A, Silfvast A, Viinikka L, Ylikorkala O (1996) High bone density in hyperandrogenic women: effect of gona-dotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement. J Clin Endocrinol Metab 81: 646 - 651PubMedCrossRefGoogle Scholar
  36. Stovall TG, Ling FW, Henry LC, Woodruff MR (1991) A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol 164(I): 1420–1425PubMedGoogle Scholar
  37. Sudik R, Hüsch K, Steller J et al. (1996) Fertility and pregnancy outcome after myomectomy in sterility patients. Eur J Obstet Gynecol Reprod Biol 65: 209–214PubMedCrossRefGoogle Scholar
  38. Thomas EJ (1996) Add-back therapy for long-term use in dys-functional uterine bleeding and uterine fibroids. Br J Obstet Gynecol 103 (Suppl 14): 18–21Google Scholar
  39. Tiltman AJ (1985) The effects of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 4: 89–96PubMedCrossRefGoogle Scholar
  40. Vollenhoven BJ, Lawrence AS, Healy DL (1990) Uterine fibroids: a clinical review. Br J Obstet Gynaecol 97: 285–298PubMedCrossRefGoogle Scholar
  41. Wallwiener D, Aydeniz B, Rimbach S, Diel IJ, Grischke EM, Rabe T, Bastert G (1996) Der Wandel des Spektrums uteruserhaltender Myomoperationen unter Einbeziehung von Endoskopie und dualer Myomtherapie. Gynäkol Geburtshilfliche Rundsch 36(3): 118–132PubMedCrossRefGoogle Scholar
  42. West CP, Lumsden MA, Hillier H, Sweeting V, Baird DT (1992) Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. Hum Reprod 7: 328–332PubMedGoogle Scholar
  43. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB (1994) Hysterectomy in the United States, 1988–1990. Obstet Gynecol 83: 549–555PubMedCrossRefGoogle Scholar
  44. Ziegler D, Bessis R, Frydman R (1991) Vascular resistance of uterine arteries: physiological effects of estradiol and progesterone. Fertil Steril 55: 775–779PubMedGoogle Scholar
  45. Zullo F, Pellicano M, Di Carlo C, De Stefano R, Marconi D, Zupi E (1998) Ultrasongraphic prediction of the efficacy of GnRH agonist therapy before laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 5(4): 361–366PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • T. Kühn

There are no affiliations available

Personalised recommendations